Greg Verdine, LifeMine CEO (via Harvard)

Greg Ver­dine will have many new C-suite friends at fun­gus biotech LifeM­ine af­ter GSK-fu­eled $175M round

A year af­ter se­cur­ing funds from Rick Klaus­ner and adding No­bel lau­re­ate William Kaelin to the board, fun­gus-fo­cused LifeM­ine Ther­a­peu­tics is ready to re­veal the Big Phar­ma part­ner it’s spent more than two years court­ing, with Hal Bar­ron in­volved, and the dry pow­der it’s been reel­ing in since Oc­to­ber.

The biotech is head­ed in­to its next chap­ter with Glax­o­SmithK­line, and an­oth­er “half a dozen” phar­mas are in the hop­per for po­ten­tial part­ner­ships, co-founder and CEO Greg Ver­dine told End­points News.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters